Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M, Jeziorski KG, Tomaszewska-Kiecana M, Láng I, Jasiówka M, Skarbová V, Centkowski P, Ramlau R, Górnaś M, Lee J, Edwards S, Habeck J, Nash E, Grechko N, Xiao JJ. Liao M, et al. Among authors: lang i. Cancer Chemother Pharmacol. 2021 Nov;88(5):887-897. doi: 10.1007/s00280-021-04338-7. Epub 2021 Aug 9. Cancer Chemother Pharmacol. 2021. PMID: 34370076 Free PMC article. Clinical Trial.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group. Lang I, et al. Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10. Lancet Oncol. 2013. PMID: 23312888 Clinical Trial.
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber RD, Piccart-Gebhart M, Di Cosimo S. Huober J, et al. Among authors: lang i. Eur J Cancer. 2019 Sep;118:169-177. doi: 10.1016/j.ejca.2019.04.038. Epub 2019 Aug 1. Eur J Cancer. 2019. PMID: 31377477 Clinical Trial.
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Muñoz M, Bermejo B, Margeli M, Antón A, Casas M, Csöszi T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodriguez J, Ramos M, López IÁ, Gal-Yam E, Garcia-Palomo A, Alvarez E, González-Santiago S, Rodríguez CA, Servitja S, Corsaro M, Rodrigálvarez G, Zielinski C, Martín M. Kahan Z, et al. Among authors: lang i. Eur J Cancer. 2021 Oct;156:70-82. doi: 10.1016/j.ejca.2021.07.004. Epub 2021 Aug 20. Eur J Cancer. 2021. PMID: 34425406 Free article. Clinical Trial.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates AS, Gelber RD, Goldhirsch A, Colleoni M, Thürlimann B, Regan MM. Rabaglio M, et al. Among authors: lang i. Breast Cancer Res Treat. 2021 Feb;185(3):697-707. doi: 10.1007/s10549-020-05981-z. Epub 2020 Nov 7. Breast Cancer Res Treat. 2021. PMID: 33159633 Clinical Trial.
1,222 results